ECOG performance status

Known as: ECOG Score, ECOG1-Performance Status, ECOG101 
A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.
National Institutes of Health

Related topics

Related topics

3 relations
CDISC Questionnaire ECOG Test Code TerminologyClinical Data Interchange Standards Consortium TerminologyZubrod Performance Status

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
OBJECTIVES Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
IMPORTANCE To integrate the patient perspective into adverse event reporting, the National Cancer Institute developed a patient… (More)
Is this relevant?
2015
2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
This phase 3 trial (Eastern Cooperative Oncology Group [ECOG] E1A06) compared melphalan, prednisone, and thalidomide (MPT-T) with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in…
AIM The aim of our study was to assess whether the Karnofsky Performance Status (KPS), the Eastern Cooperative Oncology Group… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
PURPOSE Plasma proteins [vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), carbonic anhydrase IX… (More)
  • figure 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
PURPOSE A phase III, randomized study was carried out to establish the most effective and safest treatment to improve the primary… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of…
OBJECTIVE/BACKGROUND The GONO-FOLFOXIRI regimen improved the rate of R0 secondary resection of metastases in initially… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
BACKGROUND We demonstrated that circulating tumor cell (CTC) number at baseline and follow-up is an independent prognostic factor… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2007
2007
ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival.
OBJECTIVES We tested and compared the improvement in prognostic ability related to the consideration of either ECOG performance… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Can older cancer patients tolerate chemotherapy? A prospective pilot study.
BACKGROUND To the authors' knowledge, few data currently are available regarding the tolerance to chemotherapy in older cancer… (More)
Is this relevant?